ALCAM/CD166: Cancer-related issues

Cancer Genomics and Proteomics

Volumn 7, Issue 5, 2010, Pages 231-244

  Weidle, Ulrich H ^a   Eggle, Daniela ^a   Klostermann, Stefan ^a   Swart, Guido W M ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Adhesion and aggregation; Dissemination and metastasis; Homo and heterophilic interactions; Malignant melanoma; Prognostic marker; Review; Target validation; Therapeutic intervention

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BIOLOGICAL MARKER; CD6 ANTIGEN; GELATINASE A; IMMUNOGLOBULIN RECEPTOR; MATRIX METALLOPROTEINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN RECOGNITION; BINDING AFFINITY; CELL MIGRATION; ENZYME INHIBITION; HEMATOPOIESIS; HUMAN; LIGAND BINDING; METASTASIS; NEUTROPHIL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 78149246612     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Hanahan D and Weinberg RA: The Hallmarks of Cancer Review. Cell 100: 57-70, 2000.
2. Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081, 2009.
3. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U, Haynes BF and Aruffo A: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181: 2213-2220, 1995.
4. Patel DD, Wee SF, Whichard LP, Bowen MA, Pesando JM, Aruffo A and Haynes BF: Identification and characterization of a 100-kDa ligand for CD6 on human thymic epithelial cells. J Exp Med 181: 1563-1568, 1995.
5. Swart GW: Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81: 313-321, 2002.
6. Swart GW, Lunter PC, Kilsdonk JW and Kempen LC: Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 24: 223-236, 2005.
7. Bowen MA and Aruffo A: Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions. Transplant Proc 31: 795-796, 1999.
8. Cortés F, Deschaseaux F, Uchida N, Labastie MC, Friera AM, He D, Charbord P and Péault B: HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Blood 93: 826-837, 1999.
9. Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP and Swart GW: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 152: 805-813, 1998.
10. Johnson, JP: Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 18: 345-357, 1999.
11. Zee RYL, Romero JR, Gould JL, Ricupero DA and Ridker PM: Polymorphisms in the advanced glycoprotein end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke. Stroke 37: 1686-1690, 2006.
12. Fukuhara H, Kuramochi M, Nobukuni T, Fukami T, Saino M, Maruyama T, Nomura S, Sekiya T and Murakami Y: Isolation of the TSLL1 and TSLL2 genes, members of the tumor suppressor TSCL1 gene family encoding transmembrane proteins, Oncogene 20: 5401-5407, 2001.
13. Spiegel I, Adamsky K, Eshed Y, Milo R, Sabanay H, Sarig-Nadir O, Horresh I, Scherer SS, Rasband MN and Peles M: A central role for Nec14 (SynCAM4) in Schwann cell-axon interaction and myelination. Nat Neurosci 10: 861-869, 2007.
14. Bechtel S, Rosenfelder H, Dudat A, Schmidt CP, Ernst U, Wellenreuther R, Mehrle A, Schuster C, Bahr A, Blöcker H, Heubner D, Hoerlein A, Michel G, Wedler H, Köhrer K, Ottenwälder B, Poustka A, Wiemann S and Schupp I: The full-ORF clone resource of the German cDNA consortium. BMC Genomics 8: 399-409, 2007.
15. Ikeda K and Quertermous T: Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem 279: 55315-55323, 2004.
16. Aggelis V, Craven RA, Peng J, Harnden P, Cairns DA, Maher ER, Tonge R, Selby PJ and Banks RE: Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics 9: 2118-2130, 2009.
17. Ruan W, Sassoon A, An F, Simko JP and Liu B: Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics 5: 2364-2373, 2006. (Pubitemid 46040640)
18. Hastie C, Saxton M, Akpan A, Cramer R, Masters JR and Naaby-Hansen S: Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 24: 5905-5913, 2005. (Pubitemid 43080082)
19. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M and Rosenthal A: Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205: 359-376, 2005.
20. Ochwat D, Hoja-Lukowicz D and Litynska A: N-Glycoproteins bearing beta1-6 branched oligosaccharides from the A375 human melanoma cell line analysed by tandem mass spectrometry. Melanoma Res 14: 479-485, 2004.
21. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27: 844-850, 2009.
22. Levi E, Misra S, Du J, Patel BB and Majumdar AP: Combination of aging and dimethylhydrazine treatment causes an increase in cancer-stem cell population of rat colonic crypts. Biochem Biophys Res Commun 385: 430-433, 2009.
23. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C and Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163, 2007. (Pubitemid 47175279)
24. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107, 2007. (Pubitemid 44967955)
25. Hassan NJ, Barclay AN and Brown MH: Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 34: 930-940, 2004.
26. van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, Figdor CG and Swart GW: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 276: 25783-25790, 2001.
27. Nelissen JM, Peters IM, de Grooth BG, van Kooyk Y and Figdor CG: Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol Biol Cell 11: 2057-2068, 2000.
28. Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S and Tsukita S: Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140: 885-895, 1998.
29. Zimmerman AW, Nelissen JM, van Emst-de Vries SE, Willems PH, de Lange F, Collard JG, van Leeuwen FN and Figdor CG: Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKCalpha independently of Rho-like GTPases. J Cell Sci 117: 2841-2852, 2004.
30. Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ and Schalken JA: Coordinate recruitment of E-cadherin and ALCAM to cell cell contacts by alpha-catenin. Biochem Biophys Res Commun 267: 870-874, 2000.
31. Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA and Bajorath J: CD6-ligand interactions: a paradigm for SRCR domain function? Immunol Today 18: 498-504, 1997.
32. Resnick D, Pearson A and Krieger M: The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci 19: 5-8, 1994.
33. Bowen MA, Bajorath J, Siadak AW, Modrell B, Malacko AR, Marquardt H, Nadler SG and Aruffo A: The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry. J Biol Chem 271: 17390-17396, 1996.
34. Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN and Figdor CG: Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 107: 3212-3220, 2006.
35. Ibáñez A, Sarrias MR, Farnós M, Gimferrer I, Serra-Pagès C, Vives J and Lozano F: Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 177: 1152-1159, 2006. (Pubitemid 44036619)
36. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP and Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156: 769-774, 2000.
37. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107, 2007. (Pubitemid 44967955)
38. Sawhney M, Matta A, Macha MA, Kaur J, DattaGupta S, Shukla NK and Ralhan R: Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 124: 2098-2105, 2009.
39. Verma A, Shukla NK, Deo SV, Gupta SD and Ralhan R: MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68: 462-470, 2005.
40. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S and Canevari S: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14: 1726-1733, 2008.
41. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M and Weitz J: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 101: 457-464, 2009.
42. Tomita K, van Bokhoven A, Jansen CFJ, Klemeney LA, Karthaus HFM, Vriesema J, Bussemakers MJG, Witjes JA and Schalken JA: Activated leukocyte cell adhesion molecule (ALCAM) expression is associated with poor prognosis for bladder cancer patients. UroOncology 3: 121-129, 2003.
43. Weichert W, Knösel T, Bellach J, Dietel M and Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160-1164, 2004.
44. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M and Rosenthal A: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54: 34-43, 2003.
45. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M and Rosenthal A: Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205: 359-376, 2005.
46. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O and Jiang WG: Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6: R478-487, 2004.
47. Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F and Milde-Langosch K: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112: 419-427, 2008.
48. Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denken C, Guski H, Dietel M and Kristiansen G: Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 59: 403-409, 2006.
49. Davies SR, Dent C, Watkins G, King JA, Mokbel K and Jiang WG: Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep 19: 555-561, 2008.
50. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M and Diamandis EP: Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 125: 9-14, 2009.
51. Ofori-Acquah SF and King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transi Res 151: 122-128, 2008.
52. Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D and Ofori-Acquah SF: Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett 580: 2637-2645, 2006.
53. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S and Fabbi M: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246-1253, 2007.
54. Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P and Reiss K: L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 25: 9040-9053, 2005.
55. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, Willems PH, van Muijen GN and Swart GW: Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65: 8801-8808, 2005.
56. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP and Swart GW: Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol 122: 1293-1301, 2004.
57. van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LC and Swart GW: Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 68: 3671-3679, 2008.
58. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD and Liu B: Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 6: 2737-2746, 2007.
59. Liu B, Conrad F, Roth A, Drummond DC, Simko JP and Marks JD: Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med 85: 1113-1123, 2007.
60. Piazza T, Cha E, Bongarzone I, Canevari S, Bolognesi A, Polito L, Bargellesi A, Sassi F, Ferrini S and Fabbi M: Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci 118: 1515-1525, 2005.
61. Kozbor D: Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens. Immunol Res 46: 23-31, 2010.
62. Bowen MA, Bajorath J, D'Egidio M, Whitney GS, Palmer D, Kobarg J, Starling GC, Siadak AW and Aruffo A: Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol 27: 1469-1478, 1997.